EGFR and lung cancer: For example, Kharbanda's group further demonstrated that inhibiting zDHHC20-mediated palmitoylation of EGFR in KRAS mutation-driven lung cancer blocked downstream EGFR signaling and inhibited tumor cell growth, sensitizing the efficacy of PI3K inhibitors 21.